Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab

Fig. 3

Kaplan–Meier survival estimates in patients with RR-cHL treated with anti-PD-1 monotherapy (nivolumab) according to BMI categories. PFS by BMI (a), landmark analysis of PFS by best response and BMI (b), OS in the full study cohort (c), OS by BMI (d). At a median follow-up of 16.4 months, median OS was not reached. Underweight patients had a significantly shorter OS as compared with those of normal weight (P = 0.027). PD-1 programmed cell death-1, RR-cHL relapsed and refractory classic Hodgkin Lymphoma, BMI body mass index, PFS progression-free survival, OS overall survival

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us